Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$174.72 USD

174.72
8,241,747

+0.30 (0.17%)

Updated Aug 14, 2025 04:00 PM ET

Pre-Market: $175.68 +0.96 (0.55%) 8:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (80 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sreoshi Bera headshot

Innovation Drives Robotic-Assisted Surgery: 5 Stocks to Watch

by Sreoshi Bera

Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).

Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

Kinjel Shah headshot

Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs

by Kinjel Shah

Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.

Zacks Equity Research

AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance

by Zacks Equity Research

AbbVie (ABBV) beats on first-quarter 2021 earnings and revenues. Shares up in pre-market trading.

Zacks Equity Research

Emergent (EBS) Beats on Q1 Earnings, Cuts Contract Revenue View

by Zacks Equity Research

Emergent's (EBS) earnings in the first quarter of 2021 beat estimates while revenues miss the same. It lowers guidance for revenues from CDMO services. Stock down.

Kinjel Shah headshot

Merck (MRK) Q1 Earnings & Sales Miss, COVID-19 Hurts Vaccines

by Kinjel Shah

Merck (MRK) misses Q1 estimates for earnings and sales. Stock down in pre-market.

Zacks Equity Research

Glaxo's (GSK) Q1 Earnings In Line, Sales Hit by COVID-19

by Zacks Equity Research

Glaxo's (GSK) revenues get hurt by disruption related to COVID-19 pandemic. However, robust growth in respiratory, immuno-inflammation and cancer drugs partially offset the decline.

Sanghamitra Saha headshot

Novavax Vaccine to Get U.S. Approval? ETFs to Benefit

by Sanghamitra Saha

Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.

Sweta Killa headshot

Healthcare ETFs on Radar As Q1 Earnings Unfold

by Sweta Killa

Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.

Zacks Equity Research

Strong New Drugs Sales to Aid AbbVie's (ABBV) Q1 Earnings

by Zacks Equity Research

AbbVie (ABBV) is expected to have witnessed a recovery in demand trends for new drugs amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Zacks Equity Research

Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More

by Zacks Equity Research

Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.

Zacks Equity Research

What's in Store for Emergent (EBS) This Earnings Season?

by Zacks Equity Research

On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.

Zacks Equity Research

Merck (MRK) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

Zacks Equity Research

What's in the Cards for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

Higher demand for its growth drugs is likely to have offset generic competition for Humira in the United States to boost AbbVie's (ABBV) first-quarter sales.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates

by Kinjel Shah

J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.

Zacks Equity Research

Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate

by Zacks Equity Research

Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.

Zacks Equity Research

Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter

by Zacks Equity Research

Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.

Sweta Killa headshot

Healthcare ETFs in Focus Post JNJ's Q1 Earnings Results

by Sweta Killa

Johnson & Johnson (JNJ) continued its long streak of earnings beat and outpaced revenue estimates. However, the company tightened its full-year guidance.

Zacks Equity Research

J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe

by Zacks Equity Research

J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).

Zacks Equity Research

Company News for Apr 21, 2021

by Zacks Equity Research

Companies In The News Are: JNJ, PG, PM, TRV

Madeleine Johnson headshot

Bear of the Day: OrganiGram Holdings (OGI)

by Madeleine Johnson

This cannabis stock is still being weighed down by the coronavirus pandemic.

Zacks Equity Research

Better-than-Expected Corporate Earnings

by Zacks Equity Research

Better-than-Expected Corporate Earnings

Mark Vickery headshot

P&G, J&J Beat on Earnings, Drop in Pre-Market

by Mark Vickery

We are continuing to digest the data from last week and our forward looks ahead, while also sifting through new quarterly earnings reports.

Zacks Equity Research

Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe

by Zacks Equity Research

Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.

Zacks Equity Research

J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales

by Zacks Equity Research

J&J (JNJ) beats first-quarter 2021 estimates for both earnings and sales. It boosts quarterly dividend by 5%.